bl-b01d1
biokin pharma
['lcsm,(-blcsm)', 'bl-b01d1', 'nsclc', 'sclc']
 bl-b01d1, a first-in-class egfr her3 bispecific adc. orr 45% across selected tumor types. orr 63% in previously treated egfrmut nsclc regardless of mutational background. no ild #asco23 #lcsm 
Medical Oncology 🏥 Hospital General Universitario Gregorio Marañón⎪@myESMO Faculty 🫁 ⎪Power to the patients #endlungcancer #lcsm